Drug Landscape ›
Anti-TNF ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 20
Most-reported reactions
Arrhythmia — 2 reports (10%) Arthralgia — 2 reports (10%) Colitis Ulcerative — 2 reports (10%) Depression — 2 reports (10%) Diarrhoea — 2 reports (10%) Hypertension — 2 reports (10%) Nausea — 2 reports (10%) Pulmonary Fibrosis — 2 reports (10%) Urticaria — 2 reports (10%) Vomiting — 2 reports (10%)
Source database →
Anti-TNF in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Anti-TNF approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Anti-TNF in United States?
Abu Dhabi Stem Cells Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.